Mary Kay Inc. & European Society for Dermatological Research Partner to Award Educational Research Grants Advancing Skin Health/Skin Disease
17.5.2023 19:05:00 EEST | Business Wire | Press release
Mary Kay Inc., a global leader in skin care innovation, in partnership with the European Society for Dermatological Research, recently announced its inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees at a special virtual event prior to the First International Societies for Investigative Dermatology conference in May. Grant recipients are researchers conducting groundbreaking, innovative studies in skin health and skin disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005040/en/
Mary Kay partnered with European Society for Dermatological Research (ESDR) to award inaugural Mary Kay-ESDR Skin Health/Skin Disease Research Grants. Congratulations to our 2022 recipients, Dr. Clarisse Ganier and Dr. Michael Cangkrama, who will each receive $20,000 grants to further their contributions in skin disease research. (Photo: Mary Kay Inc.)
“Mary Kay is dedicated to advancing skin and nutritional health research globally, and we know this cannot be done alone. Collaboration across industries, academic institutions, and clinicians is critical, which is why we are proud to partner with ESDR to furnish the first-ever Mary Kay-ESDR Skin Health/Skin Disease Research Grants,” said Dr. Lucy Gildea, Chief Innovation Officer, Product and Science at Mary Kay. “These grants bring this larger community together for new inspiration for the future, and Mary Kay is proud to be a part of this opportunity. We are excited to see how these recipients bring greater advancements to different aspects of skin health research.”
The Mary Kay Skin Health/Skin Disease Research Grants were announced at last year’s meeting in partnership with ESDR. The $20,000 grants were to be awarded to two researchers conducting incredible work in skin research to uncover new perspectives and invention strategies. In the months following the 2022 ESDR meeting, the company received applications from scientists across all of Europe.
The two grant awardees ultimately selected were:
- Dr. Michael Cangkrama, (Switzerland) Senior Scientist, Department of Biology, Institute of Molecular Health Sciences, ETH Zürich – Dr. Cangkrama is working on molecular and cellular mechanisms underlying the development and progression of epithelial skin cancers, the most common types of cancer in humans. His research projects will focus on investigating molecular mechanisms of squamous cancer development and the role of the tumor microenvironment using state-of-the-art approaches. He will utilize the grant to further develop his independent projects and continue to pursue positions as an independent group leader or Assistant Professor in Europe.
- Dr. Clarisse Ganier, (United Kingdom), Research Associate at the Center of Gene Therapy and Regenerative Medicine in King’s College London. Dr. Ganier is part of the Human Cell Atlas initiative – an international collaborative effort to map all cell types within the human body – to generate a comprehensive Skin Cell Atlas. As part of this work, they have created a multi-scale spatial atlas of healthy skin and basal cell carcinoma (BCC), incorporating single cell transcriptomics, in vivo optical coherence tomography, spatial global transcriptional profiling and in situ sequencing. Funding for this research will allow her to pursue her professional goals of starting her own laboratory focusing on skin cancer biology by combining multiomics data, both in vitro and ex vivo.
“Congratulations to each of our 2022 grant award recipients,” added Dr. Gildea. “These individuals were carefully chosen in collaboration with the European Society for Dermatological Research—and we are thrilled to support their research.”
“On behalf of the ESDR board, we would like to thank Mary Kay for its support of the ESDR and congratulate this year’s grant recipients for their tremendous contributions to their respective fields. A key objective of our Society is to promote innovative research in investigative dermatology and to support researchers' activities in translational skin research,” said Eli Sprecher, Chair, Scientific Program Committee of ESDR.
The sponsorship and grants, revealed leading up to the inaugural International Societies for Investigative Dermatology Conference in Tokyo, are just the latest efforts by Mary Kay to reinforce the company’s long-standing commitment to advancing skin health research and development. Mary Kay holds more than 1,600 patents for products, technologies and packaging designs in its global portfolio.
View the full Mary Kay-ESDR Skin Health/Skin Disease Research Grants Ceremony recording here.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in more than 35 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook , Instagram, and LinkedIn or follow us on Twitter.
About European Society for Dermatological Research (ESDR)
The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of about 1100. By supporting investigative dermatology and skin research, the ESDR contributes to an in-depth understanding of skin homeostasis and toward improving the health of patients suffering from skin and venereal diseases. The ESDR facilitates the exchange of information relevant to investigative dermatology between clinicians and scientists worldwide. The ESDR also organizes educational events throughout the year to further knowledge in dermatological research. For more information, please visit: https://esdr.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005040/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202628.5.2026 00:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, senior author of the NEJM manuscript and first author of the ASCO abstract, said: “Results from the HERIZON-GEA-01 published in The New England Journal of Medicine and presented in an oral presentation at ASCO provide ne
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 18:22:00 EEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 17:00:00 EEST | Press release
Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks with financing tech embedded directly into sales tools such as Salesforce, enabling 97% of lending applications to be vetted and
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 16:00:00 EEST | Press release
ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527813115/en/ ClickHouse Co-Founders (left to right): Yury Izrailevsky, Aaron Katz, Alexey Milovidov Growth When ClickHouse closed its $400 million Series D in January 2026, it
Wasabi and Liverpool FC Renew Multi-year Partnership to Scale Global Fan Growth27.5.2026 16:00:00 EEST | Press release
Wasabi Technologies, the hot cloud storage company, today announced a multi-year extension of its partnership with Liverpool Football Club (LFC), deepening its role as the club’s Official Cloud Storage Partner. The renewed deal will see Wasabi help power the next phase of LFC’s global content strategy through Wasabi AiR, the intelligent media storage service, enabling the club to move faster, scale smarter, and deliver more personalised fan experiences that bring supporters across the world closer to the club. Together, the partnership empowers LFC to create, store, find, and publish content faster, helping to deliver rapid match and social output and serve its global fanbase with richer, more dynamic storytelling. Meanwhile, LFC serves as a strategic partner in Wasabi’s worldwide expansion, with brand visibility that grows Wasabi’s partner and customer bases in key markets across Europe, Asia, and North America. A strategic global partnership spanning tech, fan engagement, brand marke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
